Skip to main content
. 2024 Mar 2;4(1):e345. doi: 10.1002/deo2.345

TABLE 2.

Histopathological findings and endoscopic mucosal atrophy.

Overall Group L Group S p‐value
Size, mm (median, range) 24 (3–170) 23 (3–160) 25 (4–170) 0.310
Macroscopic type 0.760
Type 0‐I, 0‐IIa, 0‐IIb 29/377 (7.69%) 8/84 (9.52%) 21/293 (7.17%)
Type 0‐IIc, 0‐IIa+IIc 282/377 (74.8%) 61/84 (72.6%) 221/293 (75.4%)
Type 1, 2, 3, 4, 5 66/377 (17.5%) 15/84 (17.9%) 51/293 (17.4%)
Location 0.713
Upper 120/377 (31.8%) 28/84 (33.3%) 92/293 (31.4%)
Middle 140/377 (37.1%) 33/84 (39.3%) 107/293 (36.5%)
Lower 117/377 (31.0%) 23/84 (27.4%) 94/293 (32.1%)
Invasive depth 0.256
SM1 137/377 (36.3%) 25/84 (29.8%) 112/293 (38.2%)
SM2 149/377 (39.5%) 34/84 (40.5%) 115/293 (39.2%)
MP or deeper 91/377 (24.1%) 25/84 (29.8%) 66/293 (22.5%)
Histological type 0.023
Pure differentiated 169/377 (44.8%) 29/84 (34.5%) 140/293 (47.8%)
Differentiated‐predominant mixed 110/377 (29.2%) 24/84 (28.6%) 86/293 (29.4%)
Undifferentiated 98/377 (26.0%) 31/84 (36.9%) 67/293 (22.9%)
Lymphovascular invasion 186/366 (50.8%) 42/78 (53.8%) 144/288 (50.0%) 0.700
Lymph node metastasis 68/339 (20.1%) 17/75 (22.7%) 51/264 (19.3%) 0.628
Distant metastasis 9/339 (2.65%) 5/75 (6.67%) 4/264 (1.51%) 0.031
Pathological stage 0.060
IA 227/339 (67.0%) 42/75 (56.0%) 185/264 (70.1%)
IB 44/339 (13.0%) 14/75 (18.7%) 30/264 (11.4%)
IIA 17/339 (5.01%) 4/75 (5.33%) 13/264 (4.92%)
IIB 13/339 (3.83%) 4/75 (5.33%) 9/264 (3.41%)
IIIA or IIB or IIIC 29/339 (8.55%) 6/75 (8.00%) 23/264 (8.71%)
IV 9/339 (2.65%) 5/75 (6.67%) 4/264 (1.52%)
Endoscopic mucosal atrophy 0.608
Mild, C‐1, 2 32/377 (8.49%) 9/84 (10.7%) 23/293 (7.84%)
Moderate, C‐3, O‐1 157/377 (41.6%) 32/84 (38.1%) 125/293 (42.7%)
Severe, O‐2, 3 188/377 (49.9%) 43/84 (51.2%) 145/293 (49.5%)

†Kimura‐Takemoto classification.

Abbreviations: C, closed; O, open.

Group L, Group of invasive gastric cancers diagnosed ≥10 years after H. pylori eradication; Group S, Group of invasive gastric cancers diagnosed <10 years after H. pylori eradication; SM1, submucosal invasion <0.5mm; SM2, submucosal invasion ≥0.5mm; MP, muscularis propria.

HHS Vulnerability Disclosure